The X-VENT ventilator combines the precision and independence of a piston-driven ventilation system and offers a complete set of ventilation modes
Enexor Health Systems, a wholly-owned subsidiary of Enexor Energy, has received the US Food and Drug Administration (FDA) Emergency Use Authorisation (EUA) for the immediate delivery and use of a new ventilator, dubbed X-VENT.
A medical team of physicians and respiratory therapists, led by Vanderbilt University’s Monroe Carrol Jr Children’s Hospital ventilation technology specialist Bill Walsh, has guided the designing of X-VENT to deliver the critical modes of ventilations for Covid-19 patients.
The X-VENT ventilator combines the precision and independence of a piston-driven ventilation system and delivers a complete set of ventilation modes and settings to meet patients’ needs.
Bill Walsh said: “The X-VENT is a sophisticated, complex, state-of-the-art ventilator capable of providing multiple modes of mechanical ventilation.
“The engineers did an amazing job keeping it simple, easy to use and inexpensive. It is exactly what the physicians of the world need to support their patients through acute respiratory failure.”
The X-VENT is an advanced ventilator that leverages a piston-driven air system
Enexor said that the X-VENT is one of the very few FDA EUA approved ventilators that does not feature a bag valve mask (BVM) resuscitator, which is often referred to as Ambu-bag.
The advanced ventilator X-VENT leverages a piston-driven air system controlled by a Schneider Electric industrial-grade programmable logic computer (PLC).
The X-VENT, which has been designed for many years of use, can be self-calibrated, and can easily be stored. The system is priced considerably less than the cost of a traditional ventilator to promote world-wide use and impact more lives, said the company.
Enexor has leveraged its extensive engineering design, manufacturing, and operational capabilities to rapidly design, test and manufacture the unique ventilator.
The company has already begun manufacturing ventilators, and the FDA approval allows it to ramp up manufacturing to meet the critical needs and begin delivering ventilators to hospitals in the US and across the world, within a few days.
Enexor CEO and founder Lee Jestings said: “Enexor was created to help solve major world problems.
“In responding to Covid and future pandemics, we stayed true to our mission by putting together an incredible team of medical professionals, engineers and manufacturing specialists with the ultimate mission of designing and manufacturing a durable, reliable, easy to maintain, and affordable ventilator that can be deployed at any hospital in the world to help save lives.”